Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Buffett: The current environment is not ideal for Berkshire to deploy capital

Buffett: The current environment is not ideal for Berkshire to deploy capital

金十金十2026/05/02 17:22
Show original
Golden Ten Data, May 3 – In an interview with CNBC, Buffett stated, “As far as Berkshire's capital deployment is concerned, this is not currently our ideal market environment.” Buffett mentioned that Berkshire has an excellent management team capable of taking action at the right moment and patiently waiting for suitable opportunities. He explained that although it may seem outwardly that Berkshire sometimes remains inactive, in fact, the company will act vigorously when the timing is appropriate. He admitted that the reluctance to deploy large amounts of capital is partly due to the overall high market valuation. When asked when the right time for investment would be, Buffett said that when “no one is willing to answer the phone,” the opportunity will naturally present itself.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12